|Podcasts|January 14, 2022
Pharmacy Focus: Psychedelic Pharmacy - Episode 3
Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder
Advertisement
In this episode, Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder, as well as how his own background led him to this research. In the interview, Hack said he believes a derivative could improve access as well as acceptance of the psychedelic drug.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
2
New 2025 Hypertension Management Guidelines Include Key Updates
3
Dextromethorphan Emerges as a Novel Antidepressant Pathway for Treatment-Resistant Depression
4
Preparing for the RNA Therapy Pipeline in Lipid Management
5